Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 10/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.61 |
| ▸ | PIM1 | P11309 | 6/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053320 | 0.91 | FYN (0.62) | FYNMKNK1PIM1IKBKBKCNH2 | |
| SCHEMBL4692191 | 0.89 | PIM1 (0.56) | FYNMKNK1PIM1IKBKBKCNH2 | |
| SCHEMBL1054767 | 0.86 | FYN (0.67) | FYNMKNK1PIM1KCNH2 | |
| SCHEMBL1054265 | 0.84 | FYN (0.64) | FYNMKNK1PIM1KCNH2 | |
| SCHEMBL1049259 | 0.83 | PIM1 (0.66) | FYNMKNK1PIM1KCNH2 | |
| SCHEMBL1052467 | 0.82 | FYN (0.65) | FYNMKNK1PIM1KCNH2 | |
| SCHEMBL1054998 | 0.79 | FYN (0.79) | FYNMKNK1PIM1KCNH2 | |
| SCHEMBL1054579 | 0.79 | FYN (0.79) | FYNMKNK1PIM1KCNH2 | |
| SCHEMBL1055146 | 0.78 | FYN (0.71) | FYNMKNK1PIM1KCNH2 | |
| SCHEMBL1052943 | 0.78 | FYN (0.79) | FYNMKNK1PIM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-2063962-A2 | IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER | Biogen Idec MA Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008030579-A2 | IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER | BIOGEN IDEC MA INC. (US) | 2008-03-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | FYN 666/4885MKNK1 105/4885PIM1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.